{"entity":{"id":"nct07021950","kind":"trial","name":"AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 2 trial of ivonescimab, fOLFIRI (5-FU, leucovorin, irinotecan) and bevacizumab (glioblastoma use) in colorectal cancer, run by Sun Yat-sen University, not yet recruiting.","summary":"AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07021950 by Sun Yat-sen University, with a registry enrolment figure of 130 participants, started 2025-08-10 and due to reach its primary completion in 2027-10-31. Interventions recorded: AK112; FOLFIRI; Bevacizumab. Conditions listed: Colorectal Cancer; Ivonescimab. Primary outcome: PFS. Colorectal eligibility wording from the registry: \"Pathologically confirmed locally advanced unresectable or metastatic colorectal adenocarcinoma\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07021950","url":"https://clinicaltrials.gov/study/NCT07021950"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":[],"drugs":["ivonescimab","folfiri","bevacizumab-glioma"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07021950","phase":"2","setting":"Ivonescimab (AK112) Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer: a Randomized, Controlled, Multicenter Phase II Study","sponsor":"Sun Yat-sen University","enrolled":130,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07021950/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}